Join
Live feed
·
PRReleasevia Quantisnow
OKYO Pharma Limited logo

OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain

ByQuantisnow·Wall Street's wire, on your screen.
OKYO· OKYO Pharma Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OKYO (OKYO Pharma Limited) and more on Quantisnow.